Literature DB >> 33517894

PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.

Cynthia I Campbell1, Andrew J Saxon2, Denise M Boudreau3, Paige D Wartko3, Jennifer F Bobb3, Amy K Lee3, Abigail G Matthews4, Jennifer McCormack4, David S Liu5, Megan Addis3, Andrea Altschuler6, Jeffrey H Samet7, Colleen T LaBelle7, Julia Arnsten8, Ryan M Caldeiro9, Douglas T Borst10, Angela L Stotts11, Jordan M Braciszewski12, José Szapocznik13, Gavin Bart14, Robert P Schwartz15, Jennifer McNeely16, Jane M Liebschutz17, Judith I Tsui18, Joseph O Merrill18, Joseph E Glass3, Gwen T Lapham3, Sean M Murphy19, Zoe M Weinstein20, Bobbi Jo H Yarborough21, Katharine A Bradley3.   

Abstract

BACKGROUND: Most people with opioid use disorder (OUD) never receive treatment. Medication treatment of OUD in primary care is recommended as an approach to increase access to care. The PRimary Care Opioid Use Disorders treatment (PROUD) trial tests whether implementation of a collaborative care model (Massachusetts Model) using a nurse care manager (NCM) to support medication treatment of OUD in primary care increases OUD treatment and improves outcomes. Specifically, it tests whether implementation of collaborative care, compared to usual primary care, increases the number of days of medication for OUD (implementation objective) and reduces acute health care utilization (effectiveness objective). The protocol for the PROUD trial is presented here.
METHODS: PROUD is a hybrid type III cluster-randomized implementation trial in six health care systems. The intervention consists of three implementation strategies: salary for a full-time NCM, training and technical assistance for the NCM, and requiring that three primary care providers have DEA waivers to prescribe buprenorphine. Within each health system, two primary care clinics are randomized: one to the intervention and one to Usual Primary Care. The sample includes all patients age 16-90 who visited the randomized primary care clinics from 3 years before to 2 years after randomization (anticipated to be > 170,000). Quantitative data are derived from existing health system administrative data, electronic medical records, and/or health insurance claims ("electronic health records," [EHRs]). Anonymous staff surveys, stakeholder debriefs, and observations from site visits, trainings and technical assistance provide qualitative data to assess barriers and facilitators to implementation. The outcome for the implementation objective (primary outcome) is a clinic-level measure of the number of patient days of medication treatment of OUD over the 2 years post-randomization. The patient-level outcome for the effectiveness objective (secondary outcome) is days of acute care utilization [e.g. urgent care, emergency department (ED) and/or hospitalizations] over 2 years post-randomization among patients with documented OUD prior to randomization. DISCUSSION: The PROUD trial provides information for clinical leaders and policy makers regarding potential benefits for patients and health systems of a collaborative care model for management of OUD in primary care, tested in real-world diverse primary care settings. Trial registration # NCT03407638 (February 28, 2018); CTN-0074 https://clinicaltrials.gov/ct2/show/NCT03407638?term=CTN-0074&draw=2&rank=1.

Entities:  

Keywords:  Buprenorphine; Collaborative care; Medication; Nurse care manager; Opioid use disorder; Pragmatic trial; Primary care

Mesh:

Substances:

Year:  2021        PMID: 33517894      PMCID: PMC7849121          DOI: 10.1186/s13722-021-00218-w

Source DB:  PubMed          Journal:  Addict Sci Clin Pract        ISSN: 1940-0632


  30 in total

1.  Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.

Authors:  Geoffrey M Curran; Mark Bauer; Brian Mittman; Jeffrey M Pyne; Cheryl Stetler
Journal:  Med Care       Date:  2012-03       Impact factor: 2.983

2.  Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics.

Authors:  Emily C Williams; Carol E Achtmeyer; Jessica P Young; Douglas Berger; Geoffrey Curran; Katharine A Bradley; Julie Richards; Michael B Siegel; Evette J Ludman; Gwen T Lapham; Mark Forehand; Alex H S Harris
Journal:  J Gen Intern Med       Date:  2017-10-30       Impact factor: 5.128

3.  A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice.

Authors:  Adrianne C Feldstein; Russell E Glasgow
Journal:  Jt Comm J Qual Patient Saf       Date:  2008-04

4.  Development of a Cascade of Care for responding to the opioid epidemic.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson
Journal:  Am J Drug Alcohol Abuse       Date:  2019-01-24       Impact factor: 3.829

5.  Perceptions and practices addressing diversion among US buprenorphine prescribers.

Authors:  Lewei Allison Lin; Michelle R Lofwall; Sharon L Walsh; Adam J Gordon; Hannah K Knudsen
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

6.  Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue.

Authors:  Alexander Y Walley; Danielle Farrar; Debbie M Cheng; Daniel P Alford; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2009-07-04       Impact factor: 5.128

7.  Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.

Authors:  Colleen T LaBelle; Steve Choongheon Han; Alexis Bergeron; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2015-06-26

8.  Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.

Authors:  Denise M Boudreau; Gwen Lapham; Eric A Johnson; Jennifer F Bobb; Abigail G Matthews; Jennifer McCormack; David Liu; Cynthia I Campbell; Rebecca C Rossom; Ingrid A Binswanger; Bobbi Jo Yarborough; Julia H Arnsten; Chinazo O Cunningham; Joseph E Glass; Mark T Murphy; Mohammad Zare; Rulin C Hechter; Brian Ahmedani; Jordan M Braciszewski; Viviana E Horigian; José Szapocznik; Jeffrey H Samet; Andrew J Saxon; Robert P Schwartz; Katharine A Bradley
Journal:  J Subst Abuse Treat       Date:  2020-03

9.  Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.

Authors:  Wei-Hsuan Lo-Ciganic; Walid F Gellad; Adam J Gordon; Gerald Cochran; Michael A Zemaitis; Terri Cathers; David Kelley; Julie M Donohue
Journal:  Addiction       Date:  2016-01-30       Impact factor: 6.526

10.  Addressing identification bias in the design and analysis of cluster-randomized pragmatic trials: a case study.

Authors:  Jennifer F Bobb; Hongxiang Qiu; Abigail G Matthews; Jennifer McCormack; Katharine A Bradley
Journal:  Trials       Date:  2020-03-23       Impact factor: 2.279

View more
  4 in total

Review 1.  Expanding access to medications for opioid use disorder through locally-initiated implementation.

Authors:  Jessica J Wyse; Katherine Mackey; Travis I Lovejoy; Devan Kansagara; Anais Tuepker; Adam J Gordon; P Todd Korthuis; Anders Herreid-O'Neill; Beth Williams; Benjamin J Morasco
Journal:  Addict Sci Clin Pract       Date:  2022-06-20

2.  Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.

Authors:  Eric J Hawkins; Carol A Malte; Adam J Gordon; Emily C Williams; Hildi J Hagedorn; Karen Drexler; Brittany E Blanchard; Jennifer L Burden; Jennifer Knoeppel; Anissa N Danner; Aline Lott; Joseph G Liberto; Andrew J Saxon
Journal:  JAMA Netw Open       Date:  2021-12-01

3.  Introduction to the Special Series: National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum-20 years of research informing practice.

Authors:  Andrew J Saxon; E Jennifer Edelman
Journal:  Addict Sci Clin Pract       Date:  2022-02-02

4.  Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.

Authors:  Sarah M Bagley; Laura Chavez; Jordan M Braciszewski; Mary Akolsile; Denise M Boudreau; Gwen Lapham; Cynthia I Campbell; Gavin Bart; Bobbi Jo H Yarborough; Jeffrey H Samet; Andrew J Saxon; Rebecca C Rossom; Ingrid A Binswanger; Mark T Murphy; Joseph E Glass; Katharine A Bradley
Journal:  Addict Sci Clin Pract       Date:  2021-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.